SCHEMBL16637712

SCHEMBL16637712

CCOC(=O)c1c(C)sc2nc(Cc3cccc(C#N)c3)cc(=O)n12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 13/20 0.75
GRIN2A Q12879 13/20 0.75
GRIA2 P42262 7/20 0.75
POLB P06746 2/20 0.45
GRM5 P41594 1/20 0.43
IDH1 O75874 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
SETD7 Q8WTS6 1/20 0.40
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
HCRTR1 O43613 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16636664 0.88 GRIN1 (0.78) GRIN1GRIN2AGRIA2IDH1KDM4E
SCHEMBL16645582 0.87 GRIN1 (0.76) GRIN1GRIN2AGRIA2IDH1
SCHEMBL16636747 0.87 GRIN1 (0.84) GRIN1GRIN2AGRIA2IDH1
SCHEMBL16645606 0.86 GRIN1 (1.00) GRIN1GRIN2AGRIA2
SCHEMBL16636986 0.83 GRIN1 (0.69) GRIN1GRIN2AGRIA2POLBIDH1
SCHEMBL16637149 0.82 GRIN1 (0.68) GRIN1GRIN2AGRIA2POLBIDH1
SCHEMBL16645591 0.82 GRIN2A (0.61) GRIN1GRIN2AGRIA2POLBIDH1
SCHEMBL16637259 0.81 GRIN1 (0.77) GRIN1GRIN2AGRIA2KDM4ETDP1
SCHEMBL16645472 0.77 GRIN1 (0.62) GRIN1GRIN2AGRIA2POLBIDH1
SCHEMBL16637398 0.77 GRIN2A (0.69) GRIN1GRIN2AGRIA2IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2020-05-12 US disclosed
EP-3415519-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. Hoffmann-La Roche AG (CH) 2018-12-19 EP disclosed
US-20180244694-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2018-08-30 US disclosed
EP-3055315-B1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY HOFFMANN LA ROCHE (CH) 2018-07-25 EP disclosed
US-9988400-B2 Thiazolopyrimidinones and methods of use thereof GENENTECH, INC. (US) 2018-06-05 US disclosed
EP-3055315-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. Hoffmann-La Roche AG (CH) 2016-08-17 EP disclosed
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2016-08-04 US disclosed
WO-2015052226-A1 THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY F. HOFFMANN-LA ROCHE AG (CH) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647731-B2 Thiazolopyrimidinones and methods of use thereof TPMT, THPO, CYP11B2 GRIN1 2250/4885GRIN2A 2506/4885GRIA2 2761/4885
US-20180244694-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF TPMT, THPO, CYP11B2 GRIN1 2250/4885GRIN2A 2506/4885GRIA2 2761/4885
US-20160222033-A1 THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF TPMT, THPO, CYP11B2 GRIN1 2250/4885GRIN2A 2506/4885GRIA2 2761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.